TAP Partner News During ASCO: June 2021
TAP Partner News During ASCO: June 2021
NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 American Society of Clinical Oncology Annual Meeting
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, announced that clinical data from its Phase 1/2 dose escalation study of NEXI-001 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being held virtually from June 4 – June 8, 2021.
Jazz to Present New Data at ASCO 2021 Meetings Showcasing Clinical Advances
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced that it and its investigator sponsors will present new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from June 4 – June 8, 2021. Research findings to be presented include new data Vyxeos®/Vyxeos® Liposomal (daunorubicin and cytarabine), also known as JZP351 (formerly known as CPX-351).
Carisma Therapeutics Presents Clinical Trial Design at ASCO 2021 Meeting
CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, will make a Trial-in-Progress presentation at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from June 4 – June 8, 2021. The accepted data reinforces the potential of CARISMA's proprietary chimeric antigen receptor macrophage (CAR-M) platform, as well as the importance of evaluating CAR-monocytes (CAR-Mono) as a novel and expedited immunotherapeutic pathway.